Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission

Michael J. Mauro, Brian Druker, Richard Maziarz

Research output: Contribution to journalArticle

110 Citations (Scopus)

Abstract

Imatinib mesylate therapy leads to major or complete cytogenetic response in the majority of patients with CML in the chronic phase. A subset of these patients also achieves remission at a molecular level. It is not known if such patients will require continuous therapy, or whether imatinib could be safely discontinued. This report describes divergent clinical outcomes in two patients with chronic phase CML who discontinued imatinib therapy after obtaining a molecular remission; one patient who maintained a complete molecular response throughout a period of interruption, and a second patient with overt relapse, highlighting the uncertainty of discontinuing imatinib therapy.

Original languageEnglish (US)
JournalLeukemia Research
Volume28
Issue numberSUPPL. 1
DOIs
StatePublished - May 2004

Fingerprint

Therapeutics
Cytogenetics
Uncertainty
Imatinib Mesylate
Recurrence

Keywords

  • CML
  • Discontinuation
  • Imatinib
  • Molecular response
  • Relapse

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

@article{42977e9ec9e34d3c99f4f426669f8c3e,
title = "Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission",
abstract = "Imatinib mesylate therapy leads to major or complete cytogenetic response in the majority of patients with CML in the chronic phase. A subset of these patients also achieves remission at a molecular level. It is not known if such patients will require continuous therapy, or whether imatinib could be safely discontinued. This report describes divergent clinical outcomes in two patients with chronic phase CML who discontinued imatinib therapy after obtaining a molecular remission; one patient who maintained a complete molecular response throughout a period of interruption, and a second patient with overt relapse, highlighting the uncertainty of discontinuing imatinib therapy.",
keywords = "CML, Discontinuation, Imatinib, Molecular response, Relapse",
author = "Mauro, {Michael J.} and Brian Druker and Richard Maziarz",
year = "2004",
month = "5",
doi = "10.1016/j.leukres.2003.10.017",
language = "English (US)",
volume = "28",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission

AU - Mauro, Michael J.

AU - Druker, Brian

AU - Maziarz, Richard

PY - 2004/5

Y1 - 2004/5

N2 - Imatinib mesylate therapy leads to major or complete cytogenetic response in the majority of patients with CML in the chronic phase. A subset of these patients also achieves remission at a molecular level. It is not known if such patients will require continuous therapy, or whether imatinib could be safely discontinued. This report describes divergent clinical outcomes in two patients with chronic phase CML who discontinued imatinib therapy after obtaining a molecular remission; one patient who maintained a complete molecular response throughout a period of interruption, and a second patient with overt relapse, highlighting the uncertainty of discontinuing imatinib therapy.

AB - Imatinib mesylate therapy leads to major or complete cytogenetic response in the majority of patients with CML in the chronic phase. A subset of these patients also achieves remission at a molecular level. It is not known if such patients will require continuous therapy, or whether imatinib could be safely discontinued. This report describes divergent clinical outcomes in two patients with chronic phase CML who discontinued imatinib therapy after obtaining a molecular remission; one patient who maintained a complete molecular response throughout a period of interruption, and a second patient with overt relapse, highlighting the uncertainty of discontinuing imatinib therapy.

KW - CML

KW - Discontinuation

KW - Imatinib

KW - Molecular response

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=1342343034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1342343034&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2003.10.017

DO - 10.1016/j.leukres.2003.10.017

M3 - Article

C2 - 15036945

AN - SCOPUS:1342343034

VL - 28

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - SUPPL. 1

ER -